# ADIAL Pharmaceuticals ADIAL Pharmaceuticals is an Asset Manager based in United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** United States - **Region:** North America - **Assets under management:** Undisclosed - **Website:** adialpharma.com ## Regulatory record - **Reports private funds:** No ## About ADIAL Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addiction. William Stilley serves as Chief Executive Officer. The firm's lead asset, AD04, is an investigational drug for alcohol use disorder that targets the serotonin-3 receptor, a mechanism distinct from the abstinence-based or opioid-antagonist approaches that dominate the current standard of care. ADIAL's pipeline centers solely on AD04, which completed Phase 3 clinical trials for alcohol use disorder. The company has no approved products and generates no revenue, a common posture for development-stage biotechs that must rely on equity financing to fund operations. This precision-medicine angle differentiates it from one-size-fits-all approaches to addiction pharmacotherapy. As of its most recent filings, ADIAL operated with fewer than 10 employees and held a market capitalization that has oscillated sharply. In 2021, the stock gained attention from retail investors coordinating on social media, driving intraday volatility far beyond what fundamental-development milestones would typically produce. The company has since carried out multiple capital raises, including registered direct offerings, to sustain clinical operations. ADIAL is headquartered in the United States and trades on Nasdaq under the ticker ADIL. ADIAL represents a structural archetype of pre-revenue biotech: a single-asset company whose entire value proposition rests on FDA approval of one molecule. Management's ability to finance operations without diluting existing shareholders to zero remains the binding constraint — a governance challenge common to micro-cap companies where executive compensation and survival are tied to the same binary clinical outcome. ## Sectors - Pharmaceuticals - Biotechnology ## People - William B. Stilley — Chief Executive Officer ## Questions ### Does ADIAL Pharmaceuticals have any FDA-approved products? No. As of its most recent disclosures, ADIAL has no approved products and generates no revenue. The company is entirely dependent on its single clinical-stage asset, AD04, and must raise capital through equity offerings to continue operations while pursuing regulatory approval. ### What is ADIAL's capital structure and how does it fund operations? ADIAL is a pre-revenue biotech that funds operations entirely through equity financing. The company has conducted multiple capital raises, including registered direct offerings. Its thin employee base and absence of commercial infrastructure mean burn rate and dilution risk are the principal financial metrics for any potential allocator. ### What market event brought attention to ADIAL in 2021? ADIAL's stock was swept up in retail trading activity during the 2021 meme-stock wave. Social-media-driven buying produced intraday volatility disconnected from clinical milestones. The episode did not reflect a change in fundamentals but illustrated how micro-cap biotechs can become vehicles for speculative trading. ### Who runs ADIAL Pharmaceuticals? William B. Stilley serves as Chief Executive Officer. The company operates with a small team — fewer than 10 employees per its filings — and relies heavily on external clinical contractors and consultants to execute its single-asset development program. ## Related profiles - [Dermata Therapeutics, Inc.](https://altss.com/profile/dermata-therapeutics-inc) - [Loan Artificial Intelligence Corp.](https://altss.com/profile/loan-artificial-intelligence-corp) --- Last updated: 2026-08-11T02:43:31.692Z Canonical page: https://altss.com/profile/adial-pharmaceuticals-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology